(Q37256974)

19 August 2017

1 reference

title

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy (English)

1 reference

19 August 2017

main subject

cell-intrinsic mechanism

1 reference

3

James P Allison

0 references

Sergio A Quezada

object named as

Sergio A Quezada

series ordinal

2

0 references

author name string

Karl S Peggs

series ordinal

1

1 reference

19 August 2017

publication date

1 August 2008

1 reference

19 August 2017

published in

Immunological Reviews

1 reference

19 August 2017

volume

224

1 reference

19 August 2017

page(s)

141-165

1 reference

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

19 August 2017

cites work

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3000

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3035

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2006.24.18_SUPPL.4609

The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8523

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.5120

Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1158/0008-5472.CAN-03-3025

B7-DC/PD-L2 cross-linking induces NF-kappaB-dependent protection of dendritic cells from cell death

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.4049/JIMMUNOL.178.3.1426

Identifiers

DOI

10.1111/J.1600-065X.2008.00649.X

1 reference

19 August 2017

1 reference